{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:57:30Z","timestamp":1777564650191,"version":"3.51.4"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Special Project for Prevention and Control of Major and Complicated Diseases","award":["CYW2019079"],"award-info":[{"award-number":["CYW2019079"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Polycystic ovary syndrome (PCOS), an intricate and multifactorial disease, has characteristics of diverse clinical, metabolic and endocrine disorder. It represents a primary cause of infertility in reproductive women, which seriously affects the physical and mental health of patients. Several small studies have indicated that inositol and alpha lipoic acid (ALA) supplementation can ameliorate the outcomes in terms of menstrual cyclicity, ovulation and hyperinsulinemia in PCOS women. However, there is a lack of sufficient evidence to affirm this practice. Consequently, we aim to objectively review and estimate the efficacy and safety of inositol plus ALA in adult women suffering from PCOS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and analysis:<\/jats:title>\n            <jats:p>We will retrieve PubMed, EMBASE, The Web of Science, The Cochrane Library of Controlled Trials, Clinical Trials.gov, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP database), Wan-Fang database with no specific limitations on language. Simultaneously we will manually retrieve reference lists and grey literature to acquire potential eligibility. We will restrict our search to randomized controlled trials (RCTs) of inositol in combination with ALA for PCOS. Researchers will separately identify studies, extract data and evaluate the quality of studies. We will conduct risk of bias estimates, data synthesis and analysis using Review Manager 5.3 software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results and conclusion:<\/jats:title>\n            <jats:p>The study will comprehensively determine the effectiveness and safety of inositol conjunct with ALA therapy for PCOS. Meanwhile we intend to disseminate the final findings in a peer-reviewed journal to help patients, clinicians and health policymakers select treatment strategy of PCOS by providing high-quality evidence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020696","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T23:06:20Z","timestamp":1595372780000},"page":"e20696","source":"Crossref","is-referenced-by-count":5,"title":["Effects of inositol and alpha lipoic acid combination for polycystic ovary syndrome"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2532-0783","authenticated-orcid":false,"given":"Wenwen","family":"Lei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiruo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","article-title":"Criteria, prevalence, and phenotypes of polycystic ovary syndrome","volume":"106","author":"Lizneva","year":"2016","journal-title":"Fertil Steril"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/humupd\/dmq001","article-title":"Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"16","author":"Moran","year":"2010","journal-title":"Hum Reprod Update"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1741-7015-8-41","article-title":"Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan","volume":"8","author":"Teede","year":"2010","journal-title":"BMC Med"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1093\/humrep\/der338","article-title":"Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome","volume":"26","author":"Cinar","year":"2011","journal-title":"Hum Reprod"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications","volume":"33","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Endocr Rev"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.fertnstert.2004.01.041","article-title":"Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome","volume":"82","author":"Carmina","year":"2004","journal-title":"Fertil Steril"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.fertnstert.2019.08.100","article-title":"Insulin resistance in polycystic ovary syndrome: concept versus cutoff","volume":"112","author":"Greenwood","year":"2019","journal-title":"Fertil Steril"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1210\/er.2004-0004","article-title":"The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome","volume":"26","author":"Escobar-Morreale","year":"2005","journal-title":"Endocr Rev"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0009-9120(01)00245-4","article-title":"Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease","volume":"34","author":"Sabuncu","year":"2001","journal-title":"Clin Biochem"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsbmb.2018.04.008","article-title":"Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy","volume":"182","author":"Patel","year":"2018","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1210\/jc.2005-1696","article-title":"Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome","volume":"91","author":"Gonzalez","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fphys.2016.00124","article-title":"Poly cystic ovarian syndrome: an updated overview","volume":"7","author":"El Hayek","year":"2016","journal-title":"Front Physiol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1586\/17512433.2014.925795","article-title":"Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome","volume":"7","author":"Unfer","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/09513590.2015.1054802","article-title":"Reflections on inositol(s) for PCOS therapy: steps toward success","volume":"31","author":"Nestler","year":"2015","journal-title":"Gynecol Endocrinol"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/anie.201502227","article-title":"The other\u201d inositols and their phosphates: synthesis, biology, and medicine (with recent advances in myo-inositol chemistry)","volume":"55","author":"Thomas","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/193229681000400218","article-title":"Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome","volume":"4","author":"Masharani","year":"2010","journal-title":"J Diabetes Sci Technol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/09513590.2018.1462320","article-title":"Alpha lipoic acid in obstetrics and gynecology","volume":"34","author":"Di Tucci","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40618-017-0782-z","article-title":"Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients","volume":"41","author":"Genazzani","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/09513590.2018.1540573","article-title":"Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome","volume":"35","author":"Fruzzetti","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/09513590.2015.1014784","article-title":"d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS","volume":"31","author":"Cianci","year":"2015","journal-title":"Gynecol Endocrinol"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/09513590.2017.1313972","article-title":"Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action","volume":"33","author":"De Cicco","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"R23-20230915","first-page":"1","article-title":"Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight\/obese PCOS women","author":"Artini","year":"2020","journal-title":"Gynecol Endocrinol"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R26-20230915","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/bmjebm-2018-110891","article-title":"The effect of publication bias magnitude and direction on the certainty in evidence","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:03:20Z","timestamp":1694826200000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020696"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":31,"journal-issue":{"issue":"30","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020696","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]}}}